Tirzepatide and semaglutide were associated with larger QALY gains (incremental gains of 0.35 and 0.25 over lifestyle ...

G lucagon-like peptide-1 receptor agonists, aka GLP-1 agonists, such as semaglutide -- better known as Ozempic -- have ...

Insurance coverage for GLP-1 drugs remains tight despite rising demand, with more patients facing restrictions or paying out ...

GLP-1 medications have become a popular tool for weight loss and metabolic health, but with their rise in popularity, ...

FDA ends GLP-1 drug shortage. Concerns over safety, counterfeit drugs, and high cost of brand-name versions persist; ...

GLP-1 therapy is a groundbreaking approach in the treatment of obesity and metabolic health issues. GLP-1, or glucagon-like ...

While drug developers work to mitigate the side effects associated with GLP-1–based obesity drugs, recent studies reveal that ...

Early results suggest that the formulas may help people drop even more weight—and could ... Ozempic and the expanding class of drugs known as GLP-1 receptor agonists (or GLP-1s) offer further ...

Blockbuster GLP-1 medications are changing patient care, impacting surgery volumes and reshaping the financial landscape of the healthcare industry.

At the end of the month, policies that expanded Medicare coverage for telehealth during the pandemic will expire, unless ...

GLP-1 agonists, also known as incretin mimetics ... Cleveland Clinic reports that hypoglycemia is a condition in which blood glucose levels drop below 70 mg/dL. If left untreated, it may become ...